Published Date: 22 Nov 2023
An extensive burden of nonmelanoma skin cancer (NMSC) has been linked to occupational exposure to solar ultraviolet radiation (UVR), per a study published in the November issue of Environment International.
Read Full NewsAs cancer survivorship rises, many people living with or beyond cancer face lasting physical and emotional challenges—particularly anxiety and depression, which affect about 30% of this population. Emotional distress is ...
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong prognostic information, ...
The ultimate cause of death from cancer may not be metastatic disease, as researchers have long surmised, but an infiltration of tumors into major blood vessels that cause blood clots and multiorgan failure, a one-of-a-kind ...
1.
DNA origami offers more accurate imaging in the fight against pancreatic cancer
2.
Using AI, one can find cancer risk factors.
3.
Dietary Intervention Shows Promise in Blood Cancers
4.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
5.
the contribution of cortactin to the development of cancer.
1.
Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies
2.
The Statistical Frontier of Hematology Oncology: Diagnostics, Therapies, and Future Horizons in Hematology Oncology 2025
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
5.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Navigating the Complexities of Ph Negative ALL - Part XI
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation